Deciding on the appropriate antiplatelet therapy is a challenge when treating patients with idiopathic thrombocytopenic purpura (ITP) and who are undergoing percutaneous coronary intervention (PCI). We describe here a case of PCI in a patient with chronic, refractory ITP. A 61-year-old woman presented with exertional chest pain and a low platelet count (4×10/L) at admission. Coronary angiograph...

BACKGROUND AND PURPOSE Although the use of antiplatelet therapy (APT) is associated with the risk of intracerebral hemorrhage (ICH), there are limited data on prestroke APT and outcomes, particularly among patients on combination APT (CAPT). We hypothesized that the previous use of antiplatelet agents is associated with increased mortality in ICH. METHODS We analyzed data of 82 576 patients w...

BACKGROUND The American Society of Gastrointestinal Endoscopy (ASGE) published updated guidelines in 2009 to help endoscopists manage the treatment of their patients who have been prescribed antiplatelet therapy (APT). STUDY AIM To assess the use of APT among endoscopists, and to identify factors guiding their use of APT while treating their patients. METHOD A survey questionnaire was distr...

BACKGROUND The use of antithrombotic therapy during the postoperative period after biological aortic valve replacement (AVR) in patients without thromboembolic risk factors remains controversial. Treatment with warfarin is recommended for the first 3 months after biological AVR. The use of antiplatelet therapy - mainly aspirin (ASA) - is suggested as an alternative treatment but its efficacy is...

Abstract Introduction Management of cardiovascular risk is fundamental for patients with symptomatic atherosclerosis to reduce both medium and long-term morbidity mortality. All admitted operative vascular intervention atherosclerotic arterial disease should be prescribed appropriate secondary prevention. Methods This was a single-cycle retrospective audit in patient population undergoing singl...